IN2012DN01983A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01983A
IN2012DN01983A IN1983DEN2012A IN2012DN01983A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A IN 1983DEN2012 A IN1983DEN2012 A IN 1983DEN2012A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A
Authority
IN
India
Prior art keywords
pdgfrp
csf1r
epha2
vegfr2
kit
Prior art date
Application number
Other languages
English (en)
Inventor
Jiang Shan
Xing Xinglong
Wang Qishan
Kong Ren
Original Assignee
Ascepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascepion Pharmaceuticals Inc filed Critical Ascepion Pharmaceuticals Inc
Publication of IN2012DN01983A publication Critical patent/IN2012DN01983A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1983DEN2012 2009-08-24 2010-08-20 IN2012DN01983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23627409P 2009-08-24 2009-08-24
PCT/CN2010/076199 WO2011023081A1 (en) 2009-08-24 2010-08-20 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN01983A true IN2012DN01983A (es) 2015-07-24

Family

ID=43627250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1983DEN2012 IN2012DN01983A (es) 2009-08-24 2010-08-20

Country Status (19)

Country Link
US (1) US8648086B2 (es)
EP (1) EP2470533A4 (es)
JP (1) JP2013502444A (es)
KR (1) KR20120089459A (es)
CN (1) CN102066372B (es)
AU (1) AU2010289143A1 (es)
BR (1) BR112012003462A2 (es)
CA (1) CA2769151A1 (es)
CO (1) CO6491087A2 (es)
EA (1) EA201290073A1 (es)
EC (1) ECSP12011691A (es)
IL (1) IL218114A0 (es)
IN (1) IN2012DN01983A (es)
MA (1) MA33559B1 (es)
MX (1) MX2012002317A (es)
SG (1) SG178092A1 (es)
TN (1) TN2012000042A1 (es)
WO (1) WO2011023081A1 (es)
ZA (1) ZA201200890B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004018A (es) 2008-10-14 2011-06-24 Ning Xi Compuestos y metodos de uso.
KR20110133048A (ko) 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
JP2013536806A (ja) * 2010-09-01 2013-09-26 アスセピオン ファーマスーティカル、インコーポレイテッド キナーゼ阻害剤としての重水素化複素環式化合物
BR112013013659B8 (pt) 2010-12-03 2024-02-27 Epizyme Inc Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103420895A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种4-氨基吲哚的制备方法
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
US9175032B2 (en) 2013-03-15 2015-11-03 Epizyme, Inc. Methods of synthesizing substituted purine compounds
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
JP7090958B2 (ja) * 2018-06-01 2022-06-27 アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｃｓｆ１ｒ阻害薬化合物
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
US20220204449A1 (en) * 2020-12-11 2022-06-30 Ildong Pharmaceutical Co., Ltd. Biased agonists of opioid receptors
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
EP0991406A4 (en) 1997-01-23 2000-12-13 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6500817B1 (en) * 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20060160856A1 (en) * 2002-09-05 2006-07-20 Dahl Bjarne H Diarylurea derivatives and their use as chloride channel blockers
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP2239262A3 (en) 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2588909A1 (en) 2004-11-24 2006-06-22 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2393741T3 (es) 2005-01-14 2012-12-27 Gilead Connecticut, Inc. Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
NZ563444A (en) 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8299252B2 (en) * 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
JP2007099642A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
AU2006306146A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
PT1940844E (pt) * 2005-10-28 2010-01-06 Scripps Research Inst Compostos e composições como inibidores de proteína-quinase
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
JP2009525350A (ja) 2006-02-01 2009-07-09 スミスクライン ビーチャム コーポレーション Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CN101636397B (zh) * 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途

Also Published As

Publication number Publication date
BR112012003462A2 (pt) 2016-02-23
AU2010289143A1 (en) 2012-02-16
EP2470533A4 (en) 2013-01-23
SG178092A1 (en) 2012-03-29
ECSP12011691A (es) 2012-04-30
JP2013502444A (ja) 2013-01-24
ZA201200890B (en) 2012-10-31
MA33559B1 (fr) 2012-09-01
CO6491087A2 (es) 2012-07-31
EA201290073A1 (ru) 2013-01-30
US20120122895A1 (en) 2012-05-17
CN102066372A (zh) 2011-05-18
CA2769151A1 (en) 2011-03-03
US8648086B2 (en) 2014-02-11
CN102066372B (zh) 2014-09-17
MX2012002317A (es) 2012-06-25
EP2470533A1 (en) 2012-07-04
IL218114A0 (en) 2012-04-30
TN2012000042A1 (en) 2013-09-19
KR20120089459A (ko) 2012-08-10
WO2011023081A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
IN2012DN01983A (es)
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
TN2011000673A1 (en) Bace inhibitors
MX2015010128A (es) Derivados de piridazinona macrociclicos.
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
UA112795C2 (uk) Біциклічні піразинонові похідні
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
PH12015501038A1 (en) Inhibitors of iap
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201400214A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EA201400215A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
MX2010010000A (es) Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
NZ630436A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis